Celastrol Niosome Hydrogel Has Anti-Inflammatory Effect on Skin Keratinocytes and Circulation without Systemic Drug Exposure in Psoriasis Mice
暂无分享,去创建一个
[1] H. Santos,et al. Microneedles for painless transdermal immunotherapeutic applications. , 2020, Journal of controlled release : official journal of the Controlled Release Society.
[2] J. Ahmad,et al. Nanoemulsion loaded polymeric hydrogel for topical delivery of curcumin in psoriasis , 2020 .
[3] J. Ahmad,et al. Nanoemulgel for Improved Topical Delivery of Retinyl Palmitate: Formulation Design and Stability Evaluation , 2020, Nanomaterials.
[4] Ao Wang,et al. Dendritic cells: The driver of psoriasis , 2019, The Journal of dermatology.
[5] Jia-You Fang,et al. Cutaneous delivery of [1-(4-chloro-3-nitrobenzenesulfonyl)-1H-indol-3-yl]-methanol, an indole-3-carbinol derivative, mitigates psoriasiform lesion by blocking MAPK/NF-κB/AP-1 activation. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[6] Ying Zheng,et al. Loading of water-insoluble celastrol into niosome hydrogels for improved topical permeation and anti-psoriasis activity. , 2019, Colloids and surfaces. B, Biointerfaces.
[7] Jiyong Liu,et al. Transdermal drug delivery of triptolide‐loaded nanostructured lipid carriers: Preparation, pharmacokinetic, and evaluation for rheumatoid arthritis , 2019, International journal of pharmaceutics.
[8] Jia Liu,et al. Transdermal delivery system of nanostructured lipid carriers loaded with Celastrol and Indomethacin: optimization, characterization and efficacy evaluation for rheumatoid arthritis , 2018, Artificial cells, nanomedicine, and biotechnology.
[9] C. Albanesi,et al. The Interplay Between Keratinocytes and Immune Cells in the Pathogenesis of Psoriasis , 2018, Front. Immunol..
[10] O. Abdallah,et al. Self-assembled phospholipid-based phytosomal nanocarriers as promising platforms for improving oral bioavailability of the anticancer celastrol. , 2018, International journal of pharmaceutics.
[11] S. Jacob,et al. Preparation and evaluation of niosome gel containing acyclovir for enhanced dermal deposition , 2017, Journal of liposome research.
[12] H. Tong,et al. Enhanced topical penetration, system exposure and anti‐psoriasis activity of two particle‐sized, curcumin‐loaded PLGA nanoparticles in hydrogel , 2017, Journal of controlled release : official journal of the Controlled Release Society.
[13] Mandip Singh,et al. Novel amphiphilic lipid augments the co‐delivery of erlotinib and IL36 siRNA into the skin for psoriasis treatment , 2017, Journal of controlled release : official journal of the Controlled Release Society.
[14] J. Krueger,et al. Highly Effective New Treatments for Psoriasis Target the IL-23/Type 17 T Cell Autoimmune Axis. , 2017, Annual review of medicine.
[15] Yi Fritz,et al. Antimicrobial Peptide LL37 and MAVS Signaling Drive Interferon-β Production by Epidermal Keratinocytes during Skin Injury. , 2016, Immunity.
[16] S. Feldman,et al. Current challenges and emerging drug delivery strategies for the treatment of psoriasis , 2016, Expert opinion on drug delivery.
[17] Q. Lu,et al. The Inflammatory Response in Psoriasis: a Comprehensive Review , 2016, Clinical Reviews in Allergy & Immunology.
[18] L. Iversen,et al. Identification of key research needs for topical therapy treatment of psoriasis – a consensus paper by the International Psoriasis Council , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.
[19] Ahmed Abdelbary,et al. Design and optimization of topical methotrexate loaded niosomes for enhanced management of psoriasis: application of Box-Behnken design, in-vitro evaluation and in-vivo skin deposition study. , 2015, International journal of pharmaceutics.
[20] Ying Zhang,et al. Efficacy and Safety of Tripterygium wilfordii Hook F Versus Acitretin in Moderate to Severe Psoriasis Vulgaris: A Randomized Clinical Trial , 2015, Chinese medical journal.
[21] J. O’Shea,et al. Celastrol, a Chinese herbal compound, controls autoimmune inflammation by altering the balance of pathogenic and regulatory T cells in the target organ , 2015, Clinical immunology.
[22] R. Shikiar,et al. Validity and reliability of patient reported outcomes used in Psoriasis: results from two randomized clinical trials , 2003, Health and Quality of Life Outcomes.
[23] S. Turley,et al. Stromal infrastructure of the lymph node and coordination of immunity. , 2015, Trends in immunology.
[24] S. Chaudhari,et al. Niosomes: novel sustained release nonionic stable vesicular systems--an overview. , 2012, Advances in colloid and interface science.
[25] J. Q. Rosso,et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions , 2012 .
[26] G. P. Kumar,et al. Nonionic surfactant vesicular systems for effective drug delivery—an overview , 2011 .
[27] G. Sethi,et al. Molecular targets of celastrol derived from Thunder of God Vine: potential role in the treatment of inflammatory disorders and cancer. , 2011, Cancer letters.
[28] Qiaojun He,et al. Synergistic Anti-Cancer Activity by the Combination of TRAIL/APO-2L and Celastrol , 2010, Cancer investigation.
[29] L. Boon,et al. Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 Axis1 , 2009, The Journal of Immunology.
[30] A. Gottlieb,et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. , 2009, Journal of the American Academy of Dermatology.
[31] C. Albanesi,et al. Resident skin cells in psoriasis: a special look at the pathogenetic functions of keratinocytes. , 2007, Clinics in dermatology.
[32] M. Cesta. Normal Structure, Function, and Histology of the Spleen , 2006, Toxicologic pathology.
[33] P. Lipsky,et al. The Chinese anti-inflammatory and immunosuppressive herbal remedy Tripterygium wilfordii Hook F. , 2000, Rheumatic diseases clinics of North America.